Catalent Breaks Ground at $112-Million Drug Product Manufacturing Facility

Article

Catalent recently held a groundbreaking ceremony at its Bloomington, Indiana pharmaceutical fill/finish site.

Catalent recently held a ground breaking ceremony at its Bloomington, Indiana site to mark the start of construction on a $112-million drug product manufacturing facility, which will increase fill/finish capacity at the site by 79,000 ft2. The facility will house a high-speed vial line, using both ready-to-use components and bulk filling; a high-speed flexible syringe/cartridge line; a fully automated vial inspection machine; and all associated services and support areas. Catalent Biologics plans to create up to 200 new jobs to support the increased production. Completion of both construction and recruitment are expected by the end of 2024.

Source: Catalent

Recent Videos
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.